[{"id":"astrazeneca","kind":"company","name":"AstraZeneca","route":"/companies/astrazeneca/","commit":"708b8acc4f","date":"2026-09-10","author":"Jude Gomila","message":"Sources: official-website links on thirty more institutions and thirty companies","file":"src/data/companies.ts","type":"changed","fields":[{"field":"links","after":"[{ label: \"Official website\", url: \"https://www.astrazeneca.com\" }]"}]},{"id":"astrazeneca","kind":"company","name":"AstraZeneca","route":"/companies/astrazeneca/","commit":"01c3b96cd7","date":"2026-09-10","author":"Jude Gomila","message":"Improvements batch D: Builders and investors","file":"src/data/sponsor-aliases.ts","type":"added","fields":[{"field":"id"},{"field":"label"},{"field":"kind"}]},{"id":"astrazeneca","kind":"company","name":"AstraZeneca","route":"/companies/astrazeneca/","commit":"0bdbdae6c6","date":"2026-09-09","author":"Jude Gomila","message":"Editing pass: every TL;DR and summary stands alone","file":"src/data/companies.ts","type":"changed","fields":[{"field":"tldr","before":"\"The most ADC-committed large pharma, co-owner of Enhertu and Datroway, with deep targeted-therapy and radiopharma bets.\"","after":"\"AstraZeneca is the most ADC-committed large pharma, co-owner of Enhertu and Datroway, with deep targeted-therapy and radiopharma bets.\""},{"field":"summary","before":"\"Oncology revenue >$20B. ADCs (T-DXd, Dato-DXd with Daiichi Sankyo; AZD0901 CLDN18.2; puxitatug samrotecan B7-H4; tilatamig samrotecan EGFR×MET bsADC), osimertinib, olaparib, capivasertib, durvalumab, camizestrant, sa...","after":"\"AstraZeneca's oncology revenue exceeds $20B. ADCs (T-DXd, Dato-DXd with Daiichi Sankyo; AZD0901 CLDN18.2; puxitatug samrotecan B7-H4; tilatamig samrotecan EGFR×MET bsADC), osimertinib, olaparib, capivasertib, durvalu..."}]}]